iRhythm Increases Its Value!


Shares of iRhythm Technologies (NASDAQ:IRTC), which makes wearable biosensors for detecting cardiac arrhythmias, soared 248% in 2020, according to data from S&P Global Market Intelligence. That performance made it one of the five best performing medical device stocks of the year.

The wearable technology, which offers two different device options, Zio XT and Zio AT, according to the risk level for monitoring heart diseases, provides easy use to patients and physicians the data they need.

The FDA-approved system, which also has an application called MyZio to record patients' data, has been used for years as a tool to monitor arrhythmia patients and assess atrial fibrillation risk.

This huge increase in company value last year with the effect of COVID-19 shows that the momentum in digital health technologies will continue without slowing down.

While these developments in health technologies provide physicians with easier diagnosis and treatment, they can enable patients to reach treatment earlier with early diagnosis.